Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

498 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
Santoni M, Massari F, Bracarda S, Procopio G, Milella M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Rizzo M, Cartenì G, Grande E, Matrana MR, Crabb SJ, Vau N, Sorgentoni G, Cimadamore A, Montironi R, Battelli N. Santoni M, et al. Diagnostics (Basel). 2021 Jan 18;11(1):138. doi: 10.3390/diagnostics11010138. Diagnostics (Basel). 2021. PMID: 33477676 Free PMC article.
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study.
Santoni M, Massari F, Grande E, Procopio G, Matrana MR, Rizzo M, De Giorgi U, Basso U, Milella M, Iacovelli R, Aurilio G, Incorvaia L, Buti S, Caffo O, Fornarini G, Carrozza F, Mollica V, Rizzo A, Farag F, Molina-Cerrillo J, Battelli N. Santoni M, et al. Target Oncol. 2021 Sep;16(5):625-632. doi: 10.1007/s11523-021-00828-z. Epub 2021 Aug 2. Target Oncol. 2021. PMID: 34338966
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.
Santoni M, Massari F, Bracarda S, Grande E, Matrana MR, Rizzo M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Molina-Cerrillo J, Mollica V, Rizzo A, Battelli N. Santoni M, et al. Eur Urol Focus. 2022 Nov;8(6):1696-1702. doi: 10.1016/j.euf.2022.02.004. Epub 2022 Feb 19. Eur Urol Focus. 2022. PMID: 35193819
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison.
Santoni M, Aurilio G, Massari F, Grande E, Matrana MR, Rizzo M, De Giorgi U, Incorvaia L, Martignetti A, Molina-Cerrillo J, Zabalza IO, Mollica V, Rizzo A, Battelli N, Porta C. Santoni M, et al. Clin Genitourin Cancer. 2022 Jun;20(3):285-295. doi: 10.1016/j.clgc.2022.02.003. Epub 2022 Feb 19. Clin Genitourin Cancer. 2022. PMID: 35305916
A Systematic Review and Meta-Analysis of the Role of Immune Checkpoint Inhibitors (ICI) as Adjuvant Treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC).
Monteiro FSM, Soares A, Souza VC, Sperandio RC, Grande E, Santoni M, Fay AP, Sasse AD. Monteiro FSM, et al. Among authors: santoni m. Clin Genitourin Cancer. 2022 Oct;20(5):391-398. doi: 10.1016/j.clgc.2022.04.008. Epub 2022 Apr 25. Clin Genitourin Cancer. 2022. PMID: 35595632 Review.
498 results